drugset
drugset / Trial / NCT00815906

Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

NCT00815906 ↗

Phase 1 Completed 20 enrolled Pfizer Emergent Product Development Seattle LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of single doses of SBI-087 in Japanese subjects with rheumatoid arthritis.

Timeline

Start
2008-12
Primary completion
2012-04
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SBI-087 Protein / enzyme biologic 0.15 mg Intravenous
Subject SBI-087 Protein / enzyme biologic 0.5 mg Intravenous
Subject SBI-087 Protein / enzyme biologic 100 mg Intravenous
Subject SBI-087 Protein / enzyme biologic 200 mg Intravenous

Indications

rheumatoid arthritis